EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Pharmaceutical Quality Management in the American Drug Manufacturing Industry: FDA Standards, Quality Systems and Process Control
Imagine a plant that makes a blood pressure tablet Every batch passes its final test but nobody noticed that the blending step has been drifting for months One day a batch fails dissolution Then another Then the FDA shows up
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
Identification of flavonoids from natural products against hyperlipidaemia through computational approaches
Over the centuries hyperlipidaemia has been recognised as a major risk factor contributing to cardiovascular disease CVD Current research increasingly explores natural compounds such as flavonoids for their potential lipidlowering effects This study evaluated pharmacological potential
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Evolving Trends and Strategies in Pharmaceutical Marketing: Focus on the American Market
Kate Williamson
This exploration delves into evolving trends and strategies in pharmaceutical marketing, with a focus on the dynamic American market. From digital transformation and patient-centric approaches to data...
-
2
How Decentralized Clinical Trials Are Changing U.S. Research
Lakshmi
Decentralized clinical trials (DCTs) are moving U.S. pharmaceutical research out of the hospital and into patients' homes. Supported by telehealth, electronic consent, direct-to-patient drug deliv...
-
3
Pharmacovigilance in the Age of AI: Enhancing Drug Safety with Technology
Kate Williamson
AI is revolutionizing pharmacovigilance by enhancing drug safety through advanced technologies like machine learning and natural language processing. These innovations enable efficient, accurate detec...
-
4
From Miracle Drugs to Superbugs: Understanding Antimicrobial Resistance
Kate Williamson
AMR is characterized as one of the most severe threats to global health since it weakens antibiotics, antiviral drugs, antifungal drugs and antiparasitic drugs. This article is based on the developmen...
-
5
Transforming Trials: Modernizing Clinical Research for a Healthier Tomorrow
Kate Williamson
Embracing technological innovations, patient-centric approaches, and regulatory advancements, modernizing clinical trials is revolutionizing healthcare. From decentralized trials and blockchain for tr...
press releasesRead more...
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent BioSolutions Inc announced that it has received a modification exercising an option period under its existing delivery order valued at up to million to supply BioThrax Anthrax Vaccine Adsorbed to the US Department of War DoW The first delivery which is valued at approximately
Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals
Evommune Inc a clinicalstage biotechnology company developing therapies for chronic inflammatory diseases and Hinova Pharmaceuticals Inc SSE today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater China
Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding €0.5 Billion
AGC Biologics has expanded its existing longterm manufacturing agreement with a global pharmaceutical company adding a second supply node at the CDMOs Copenhagen facility The expansion which builds on the existing agreement anchored at AGC Biologics
Newleos Announces $15.5 Million NIH Grant and Receipt of FDA Fast Track Designation for NTX-2001 to Treat Substance Use Disorders
Newleos Therapeutics Inc a clinicalstage biotechnology company developing innovative treatments for neuropsychiatric disorders today announced that the National Institute on Drug Abuse NIDA part of the National Institutes of Health NIH has awarded the company up to million to fund the development o...
Events Read more...
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
10 - 12
Nov 2026Lab Asset & Facility Management Summit
The Westin Boston Seaport Dist...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
LATEST NEWSRead more...
Polaris Rx Selected by Bristol Myers Squibb to Dispense ZENBEXUS™ (iberdomide), the First FDA-Approved CELMoD Therapy for Multiple Myeloma
Polaris Rx announced today that it has been selected by Bristol Myers Squibb to dispense ZENBEXUS iberdomide the first cereblon E ligase modulator CELMoD therapy approved by the US Food and Drug Administration FDA ZENBEXUS is approved in combination with daratumumab
Moleculent Introduces Glimt, the First Automated Instrument for Functional Profiling of Cell-Cell Interactions in Human Tissue
Moleculent AB the life sciences technology company pioneering functional profiling today announced Glimt an automated platform that detects cellcell interactions directly in formalinfixed paraffinembedded FFPE tissue The Glimt platform is now available to selected academic
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement
Rhythm Pharmaceuticals Inc announced an amendment to the global exclusive license agreement with LG Chem Ltd for bivamelagon an investigational oral smallmolecule melanocortin receptor MCR agonist The Company also announced a fiveyear term loan facility led by KKR
SCIEX Launches LeadScape Compatible with SCIEX OS Software to Accelerate High-Throughput Drug Candidate Evaluation
SCIEX a Danaher company and leader in life science analytical technologies today announced the launch of LeadScape compatible with SCIEX OS software a new highthroughput workflow solution that accelerates drug candidate evaluation Developed by Sound Analytics the software
Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
Denali Therapeutics Inc announced that AVLAYAH tividenofusp alfaeknm has been recognized as the Best Biotechnology Product of by The Galien Foundation AVLAYAH is the first biologic approved by the US Food and Drug Administration FDA that is specifically designed to cross the bloodbrain barrier and...
Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors
Doximity Inc the leading digital platform for US medical professionals has launched DoseCheck a free additional safety layer in Doximity Ask that instantly checks every AIgenerated medication dosing claim against a structured drug database to reduce treatment
